|
|
LSP is one of the world's largest specialized healthcare and biotechnology investment firms. With a history dating back to the late eighties, LSP has grown into a global firm with offices in Amsterdam, Munich and Boston. LSP's investment strategy allows for investments in start-up companies in need of first round venture funding, but also in companies seeking later-stage funding, such as for product development or commercial rollouts. LSP's main areas of focus include drug discovery and development, medical devices, diagnostics, industrial biotech, food & agriculture, and bio materials. Target investee companies typically fall within the EURO 50 million to EURO 1 billion market cap range. LSP's investor base originates from the Benelux, Germany, Switzerland, the UK, the Nordic countries and the U.S. Total funds raised to date are at approximately EURO 650 million. Investments per company typically range in size from EURO 1 million up to EURO 15 million over the life of an investment. The firm launched its Euronext-listed LSP Life Sciences Fund in April 2011, with the aim to provide investors with access to the high tech and high growth sector of publicly-traded life sciences companies. In 2017, LSP launched LSP HEF 2 with a fund volume of EUR 280 million targeting investment opportunities in private medical technology companies which offer products that can both improve the quality of patient care and lower healthcare spending.
|
